Loading
Breast Cancer Treatment Studies / Advanced Radiotherapy Techniques · Journal article
World Journal of Nuclear Medicine · August 12, 2026
Encouraging direction, but not yet definitive.
This phantom dosimetry study measured organ doses from two APBI brachytherapy techniques using thermoluminescent dosimeters placed in an anthropomorphic female phantom. Multicatheter interstitial brachytherapy (MIB) delivered lower doses to the heart (19.1% vs. 30.9% prescribed dose with MammoSite) and ipsilateral lung (21.6% vs. 23.5%), with superior dose conformality, but these findings are specific to the phantom geometry and require validation in clinical patient series.
Anthropomorphic phantom dosimetry comparison study. Anthropomorphic Rando female phantom; not a human population study. Intervention: Multicatheter interstitial brachytherapy (MIB) with Ir-192 high-dose rate irradiation. Compared with: MammoSite balloon brachytherapy (MBS) with Ir-192 high-dose rate irradiation.
MBS delivered significantly higher dose to heart: 30.9% of prescribed dose vs. MIB 19.1% MBS delivered higher ipsilateral lung dose: 23.5% vs. MIB 21.6% of prescribed dose MIB achieved superior dose conformality with higher V150 and V200 values and lower dose nonuniformity ratio (0.218 vs. 0.264)
No comparison of clinical outcomes, recurrence, or late toxicity; surrogate dosimetric endpoint only
These findings suggest MIB may be preferred for left-sided breast cancers where organ sparing is critical, but the authors explicitly state this must be confirmed with patient-specific studies before clinical adoption. Clinicians should not apply these phantom results directly to treatment selection without clinical validation.
A rigorous phantom dosimetry study with direct physical measurements showing MIB superiority in OAR sparing over MBS, but limited to in vitro conditions and requiring confirmation in patient-specific studies.
As stated by the source record.
Quoted from the source exactly as published.
These findings suggest MIB may be preferred for left-sided breast cancers where organ sparing is critical, but the authors explicitly state this must be confirmed with patient-specific studies before clinical adoption. Clinicians should not apply these phantom results directly to treatment selection without clinical validation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract For breast cancer patients, accelerated partial breast irradiation (APBI) using brachytherapy provides a highly conformal treatment option. Although planning studies frequently compare brachytherapy techniques, direct measurements of doses to organs at risk (OARs) are scarce. This study hypothesized that multicatheter interstitial brachytherapy (MIB) would demonstrate superior OAR sparing compared to MammoSite balloon brachytherapy (MBS). This research utilized physical dosimetry within an anthropomorphic phantom to quantitatively evaluate and compare the OAR doses from MIB and MBS using an anthropomorphic Rando female phantom; treatment plans for MIB and MBS were designed according to the American Brachytherapy Society/Radiation Therapy Oncology Group formalism to deliver 3.4 Gy per fraction. High-sensitivity thermoluminescent dosimeters (TLD-100H) were placed at key OAR sites including the heart, lungs, ribs, spinal cord, sternum, and skin. Ir-192 high-dose rate irradiation was performed and measured doses were compared against treatment planning system (TPS) calculations and protocol limits. Both techniques successfully met the prescribed target coverage. However, MIB demonstrated superior OAR sparing compared to MBS. TLD measurements revealed that MBS delivered significantly higher doses to the heart (30.9% vs. 19.1% prescribed dose), and the ipsilateral lung (23.5% vs. 21.6%) relative to MIB. Notably, the TPS systematically overestimated superficial doses to areas like the skin, highlighting limitations of algorithmic models in heterogeneous tissues. While MIB provided more conformal target coverage (higher V150 and V200 values) with greater dose homogeneity (dose nonuniformity ratio: 0.218 vs. 0.264). Although both MIB and MBS are safe and viable APBI techniques, but under the specific conditions of this phantom, MIB offered dosimetric advantages for heart and lung sparing. Under the specific conditions of this anthropomorphic phantom study, MIB demonstrated dosimetric advantages for heart and lung sparing compared to MBS. These findings suggest MIB may be the preferred option for left-sided breast cancers when OAR sparing is critical, but this should be confirmed with patient-specific studies.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.